CYP19A1 and breast carcinoma: Thus, the best possible therapeutic approach for eliminating TICs and possibly eradicating ER+ breast cancer could be combining a phytoestrogen or another DAXX-promoting agent with an aromatase inhibitor (summarized in Fig. 10).